• Live
    • Audio Only
  • google plus
  • facebook
  • twitter
News > Russia

Sputnik V COVID Vax Brings Russia and Lat Am Closer Together

  • Upon arriving on the global pandemic scene as the first COVID vaccine, dismissed and ridiculed by Western countries, Russia's Sputnik V vaccine not only has been rehabilitated; it's also emerging as a powerful tool of influence abroad for President Vladimir Putin.

    Upon arriving on the global pandemic scene as the first COVID vaccine, dismissed and ridiculed by Western countries, Russia's Sputnik V vaccine not only has been rehabilitated; it's also emerging as a powerful tool of influence abroad for President Vladimir Putin. | Photo: Twitter @leftylabourtech

Published 16 April 2021
Opinion

Russia's Sputnik V vaccine is helping Moscow regain its foothold in Latin America, a territory traditionally viewed by the U.S. as its own backyard, according to an April 12 Associated Press report. 

The Gamaleya Institute's Sputnik V COVID vaccine has been registered to date in 60 countries worldwide with a combined population of 3 billion people, including 13 Latin American and Caribbean nations.

RELATED:

Fernandez Asks Russia to Guarantee Vaccines for Argentina

A survey conducted in nine countries, YouGov's March survey, indicated that Russia is seen as the most trusted vaccine producer alongside the U.S. with Sputnik V – the world's first registered jab – which stands out as the most recognizable brand: 74 percent of respondents have heard of the Russian vaccine; Pfizer/BioNTech ranked second (69 percent), and AstraZeneca ranked third (60 percent).

The same trend is observed in Latin America, according to Juan Martin Gonzalez Cabañas, a geopolitical analyst and political consultant from Argentina at Vision & Global Trends, who has researched public opinion surveys in Argentina, Brazil, Mexico, Peru, and Chile. In his opinion, there is quite a high level of trust in the Russian jab among Latin America's nations.

"The main aspect that led to these levels of trust was the beginning of the vaccination campaign, and that after a couple of months already in the field, this vaccine has shown no major adverse effects," Gonzalez Cabañas notes. "In the case of Argentina (and this logic can be applied to the entire region), the paper published in The Lancet was a turning point, a true 'watershed,' the spread of this publication generated a greater perception of trust."

When Russia gave the green light to Sputnik in August 2020, a wave of smearing reports from the Western press ensued right away. However, a February 2021 publication in The Lancet, the weekly peer-reviewed general medical journal, recognized the Russian jab as safe and effective and upended the tide of hostile media reviews.

On 13 April, it was reported by Argentinian health authorities that 94 percent of Sputnik V first-dose recipients produced specific antibodies, and those with two doses had developed specific antibodies in 100 percent of cases. 

Meanwhile, in Brazil, registration of the vaccine was discussed at the presidential level, and they agreed to organize supplies and production of the jab in the South American country. In mid-March 2021, it was revealed that the U.S. Department of Health had pressured the Brazilian government not to accept Russia's Sputnik V vaccine, despite Brazil's soaring COVID-related death toll.

The Associated Press admits that the US "has largely missed an opportunity to engage with Latin American governments during the pandemic," said Tom Shannon, a former under-secretary of state. In contrast, Russia has seized and capitalized the opportunity to bolster its cooperation around the region, which has already "caused consternation in US diplomatic circles," according to the media outlet.

Comment
0
Comments
Post with no comments.